The data are in! Unimolecular multiagonists have demonstrated efficacy by concurrent activation of hormone receptors that affect energy homeostasis. During this dinner symposium, learn how emerging agents offer robust glucose control, with a low risk of hypoglycemia, as well as weight loss.

Looking for more on this topic? Consider the below activities hosted by our education partner, Medical Learning Institute:

• Highlights from ADA and ENDO 2022 | Beyond Glycemic Control: Enhancing Glucose Metabolism and Energy Homeostasis Through Dual Agonism of Incretins
• Potential Benefits of Incretins Beyond Glycemic Control in T2D
• Demystifying the Evolving Science and Potential Role of Incretins in T2D

Endocrinologists, diabetologists, and endocrinology fellows, NPs, PAs, who provide care for individuals with T2D in the US

Upon completion of this activity, learners will be able to:

• Plan strategies to address unmet needs, including treatment initiation and escalation and shared decision-making, for diverse patient populations with T2D
• Assess the clinical implications of emerging evidence regarding the incretin effect and the roles of GLP-1 and GIP
• Relate the pathophysiology of GLP-1 and GIP to potential benefits of agonism of multiple receptors that affect energy homeostasis and the MOA of novel therapies
• Evaluate efficacy and safety data of novel dual agonists for T2D
• Interpret the clinical implications of the efficacy and safety data of novel dual agonists for T2D
• Assess preliminary clinical data for novel dual/triple agonists in early phase development and their potential benefits and risks

Juan Frias, MD – Program Chair
Velocity Clinical Research
Los Angeles, CA

Ildiko Lingvay, MD, MPH, MSCS
Department of Internal Medicine/Endocrinology
Department of Population and Data Sciences
UT Southwestern Medical Center
Dallas, TX

David D'Alessio, MD
Division of Endocrinology and Metabolism
Duke University School of Medicine
Durham, NC

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

• Juan Frias, MD: Eli Lilly - Advisory Board, Research Grant, Speaker; Boehringer Ingelheim - Advisory Board, Research Grant; Altimmune - Advisory Board, Research Grant; Merck - Advisory Board, Research Grant, Speaker; Novo Nordisk - Advisory Board, Research Grant
• Ildiko Lingvay, MD, MPH, MSCS: Novo Nordisk - Advisory Board, Research Grant; Boehringer Ingelheim - Advisory Board, Research Grant; Sanofi - Advisory Board, Research Grant; Mylan - Reseach Grant; Merck - Research Grant, Advisory Board; Pfizer - Research Grant; Intarcia - Advisory Board; Bayer - Advisory Board; Intercept - Advisory Board; AstraZeneca - Advisory Board; Lilly - Advisory Board
• David D'Alessio, MD: Eli Lilly - Advisory Board, Research Grant; Sun Pharma - Advisory Board; Merck - Research Grant

The following committee member who planned and reviewed content for this activity reported no relevant financial relationships:

• Beret Casey, MD, Essentia Health

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by educational grant from Lilly USA.